Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543959 | 1.00 | AVPR1A (0.53) | AVPR1AKCNH2ACHEDRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2538014 | 0.99 | AVPR1A (0.53) | AVPR1AKCNH2ACHEDRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2538017 | 0.99 | AVPR1A (0.53) | AVPR1AKCNH2ACHEDRD2SLC6A4 | |
| SCHEMBL2545618 | 0.93 | AVPR1A (0.53) | AVPR1AKCNH2SCD | |
| SCHEMBL2545622 | 0.93 | AVPR1A (0.53) | AVPR1AKCNH2SCD | |
| Hydrochloric Acid SCHEMBL2538260 | 0.92 | AVPR1A (0.53) | AVPR1AKCNH2SCD | |
| Hydrochloric Acid SCHEMBL2538257 | 0.92 | AVPR1A (0.53) | AVPR1AKCNH2SCD | |
| SCHEMBL2544627 | 0.88 | AVPR1A (0.58) | AVPR1AKCNH2 | |
| SCHEMBL2538862 | 0.88 | AVPR1A (0.58) | AVPR1AKCNH2 | |
| SCHEMBL2538866 | 0.88 | AVPR1A (0.58) | AVPR1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571879-B1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | claimed |
| US-8481528-B2 | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | claimed |
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | claimed |
| EP-2571879-B1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-8481528-B2 | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481528-B2 | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481528-B2 | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885KCNH2 875/4885ACHE 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.